← Back to Clinical Trials
Recruiting NCT07609628

NCT07609628 Effect of Silicon Oil on Retinal Electrical Functions Using Multifocal Electroretinogram

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07609628
Status Recruiting
Phase
Sponsor Minia University
Condition Rhegmatogenous Retinal Detachment
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-02-01
Primary Completion 2026-07-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Multi focal electroretinogram

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-02-01 with a primary completion date of 2026-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Retinal detachment is one of the leading causes for permanent vision loss.Incidence of Rheugmatogenous Retinal Detachment (RRD) about 10.5 people per 100,000 population pars plana vitrectomy is the most popular and effective surgical options. Tamponade agents as silicone oils are used to restore intraocular volume and apply surface tension to the detached retinal surface Silicone oil (SO) is a liquid containing polymerized siloxane with organic side chains. It has a high thermal stability, is hydrophobic, and chemically inert. The use of silicone oils as intraocular tamponades dates from 1962.

Eligibility Criteria

Inclusion Criteria: \- Patients with primary rhegmatogenous retinal detachment Exclusion Criteria: * Patients with history of previous intraocular surgery. * Patients with combined traction-rhegmatogenous retinal detachment * Patients with ocular disease as glaucoma ,degenerative myopia,age related macular degeneration * Patients with poor fixation. * Uncooperative patients. * Patients with retinopathy. * emulsified SO or complicated SO removal were excluded from this study

Contact & Investigator

Central Contact

Amany Nady Mohammed Mohammed, Resident

✉ drmonmonnady92@gmail.com

📞 +201151849593

Principal Investigator

Mahmoud Mohammed M. Genedy, Professor

STUDY CHAIR

Department of Ophthalmology, fuculty of medicine,Minia University

Frequently Asked Questions

Who can join the NCT07609628 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Rhegmatogenous Retinal Detachment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07609628 currently recruiting?

Yes, NCT07609628 is actively recruiting participants. Contact the research team at drmonmonnady92@gmail.com for enrollment information.

Where is the NCT07609628 trial being conducted?

This trial is being conducted at Minya, Egypt.

Who is sponsoring the NCT07609628 clinical trial?

NCT07609628 is sponsored by Minia University. The principal investigator is Mahmoud Mohammed M. Genedy, Professor at Department of Ophthalmology, fuculty of medicine,Minia University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology